Pub Date : 2023-11-28DOI: 10.46439/signaling.1.020
Suridh Adhikari, A. Azhdarinia, M. Kolonin
Progression to metastases remains the overriding cause of cancer-associated mortality. Metastatic cancer is not amenable to surgery and its treatment is further complicated by the development of therapy resistance often observed at advanced cancer stages. Early detection of metastases is therefore critical but has been limited by the lack of probes that can effectively localize them. Similar challenges persist with therapeutics specifically targeting metastasized cancer cells. Thus, agents that specifically target disseminating tumor cells at an early stage could produce new theranostic applications and be transformative for the survival of patients with advanced cancers. Recent studies have described new approaches for early detection and targeted eradication of metastatic cancer. Here we summarize the results from preclinical validation of the experimental probes reported to date.
{"title":"Probes for cancer metastasis imaging and therapeutic targeting","authors":"Suridh Adhikari, A. Azhdarinia, M. Kolonin","doi":"10.46439/signaling.1.020","DOIUrl":"https://doi.org/10.46439/signaling.1.020","url":null,"abstract":"Progression to metastases remains the overriding cause of cancer-associated mortality. Metastatic cancer is not amenable to surgery and its treatment is further complicated by the development of therapy resistance often observed at advanced cancer stages. Early detection of metastases is therefore critical but has been limited by the lack of probes that can effectively localize them. Similar challenges persist with therapeutics specifically targeting metastasized cancer cells. Thus, agents that specifically target disseminating tumor cells at an early stage could produce new theranostic applications and be transformative for the survival of patients with advanced cancers. Recent studies have described new approaches for early detection and targeted eradication of metastatic cancer. Here we summarize the results from preclinical validation of the experimental probes reported to date.","PeriodicalId":72543,"journal":{"name":"Cell signaling","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139225021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-27DOI: 10.46439/signaling.1.019
Andrea Frustaci, R. Verardo, C. Chimenti
{"title":"Pathogenic contribute of unaffected cardiac cells in female Fabry cardiomyopathy","authors":"Andrea Frustaci, R. Verardo, C. Chimenti","doi":"10.46439/signaling.1.019","DOIUrl":"https://doi.org/10.46439/signaling.1.019","url":null,"abstract":"","PeriodicalId":72543,"journal":{"name":"Cell signaling","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139233306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-24DOI: 10.46439/signaling.1.017
Wen Su, Rong Cao, Qijun Wan, Hui-Yao Lan
Recent studies have shed light on the pivotal roles of estrogen in various pathophysiological processes related to kidney diseases. However, the precise mechanisms governing the estrogen actions remain enigmatic. The downstream impacts of estrogen primarily hinge on estrogen receptors (ERs), namely ERα (NR3A1) and ERβ (NR3A2). Building upon our previous finding that ERβ participates in subcutaneous adipose tissue browning in female mice, our recent study found that ERβ functions to protect kidney from progressive renal fibrosis by inactivating transforming growth factor-β (TGF-β)/Smad3 signaling. In the normal kidney, ERβ is highly expressed by proximal tubular epithelial cells but it is lost when kidney becomes fibrotic. In contrast, activation of ERβ inhibits kidney fibrosis. Mechanistically, we uncovered that ERβ can bind to Smad3, thereby transcriptionally downregulating Smad3 and inhibiting TGF-β1/Smad3-mediated renal fibrosis. Thus, ERβ is protective in renal fibrosis and may have therapeutic potential for chronic kidney disease.
{"title":"Commentary: Role of estrogen receptor β in kidney disease","authors":"Wen Su, Rong Cao, Qijun Wan, Hui-Yao Lan","doi":"10.46439/signaling.1.017","DOIUrl":"https://doi.org/10.46439/signaling.1.017","url":null,"abstract":"Recent studies have shed light on the pivotal roles of estrogen in various pathophysiological processes related to kidney diseases. However, the precise mechanisms governing the estrogen actions remain enigmatic. The downstream impacts of estrogen primarily hinge on estrogen receptors (ERs), namely ERα (NR3A1) and ERβ (NR3A2). Building upon our previous finding that ERβ participates in subcutaneous adipose tissue browning in female mice, our recent study found that ERβ functions to protect kidney from progressive renal fibrosis by inactivating transforming growth factor-β (TGF-β)/Smad3 signaling. In the normal kidney, ERβ is highly expressed by proximal tubular epithelial cells but it is lost when kidney becomes fibrotic. In contrast, activation of ERβ inhibits kidney fibrosis. Mechanistically, we uncovered that ERβ can bind to Smad3, thereby transcriptionally downregulating Smad3 and inhibiting TGF-β1/Smad3-mediated renal fibrosis. Thus, ERβ is protective in renal fibrosis and may have therapeutic potential for chronic kidney disease.","PeriodicalId":72543,"journal":{"name":"Cell signaling","volume":"26 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139241934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-17DOI: 10.46439/signaling.1.015
Wenyu Li, Liuqing Wang, Youjun Wang, Lian He
Optogenetic-based genetically encoded Ca2+ actuators (GECA) have been developed to enable remote control of Ca2+ entry into cells. However, current blue light-dependent tools either lack high calcium selectivity or exhibit crosstalk with other targets, raising concerns about potential side effects. In this commentary, we present our successful design of a single-component optogenetic Ca2+ ion channel (LOCa) that selectively elevates cytoplasmic Ca2+ concentration with high spatial and temporal resolution. Furthermore, LOCa has demonstrated promising applications in regulating Ca2+-dependent cellular physiological responses and investigating diseases through animal models.
{"title":"Development of an authentic light-activated calcium channel","authors":"Wenyu Li, Liuqing Wang, Youjun Wang, Lian He","doi":"10.46439/signaling.1.015","DOIUrl":"https://doi.org/10.46439/signaling.1.015","url":null,"abstract":"Optogenetic-based genetically encoded Ca2+ actuators (GECA) have been developed to enable remote control of Ca2+ entry into cells. However, current blue light-dependent tools either lack high calcium selectivity or exhibit crosstalk with other targets, raising concerns about potential side effects. In this commentary, we present our successful design of a single-component optogenetic Ca2+ ion channel (LOCa) that selectively elevates cytoplasmic Ca2+ concentration with high spatial and temporal resolution. Furthermore, LOCa has demonstrated promising applications in regulating Ca2+-dependent cellular physiological responses and investigating diseases through animal models.","PeriodicalId":72543,"journal":{"name":"Cell signaling","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139317889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-03DOI: 10.46439/signaling.1.014
Li Tan, Juan Ren
The prognosis of brain metastases in non-small cell lung cancer (NSCLC) is poor, and patients with EGFR mutations are more likely to have brain metastases. The epidermal growth factor receptor (EGFR) gene status has changed the direction of treatment for NSCLC patients with brain metastases. The development of EGFR tyrosine kinase inhibitors (EGFR-TKI) has prolonged the survival time of NSCLC patients with brain metastases. The treatment of patients with NSCLC brain metastases should be individualized according to the clinical symptoms, tumor stage, and different gene mutation status. As cancer is heterogeneous at the molecular level, related biomarker studies looking for individualized characteristics are recommended.
{"title":"The value of EGFR in individualized treatment for brain metastases in non-small cell lung cancer","authors":"Li Tan, Juan Ren","doi":"10.46439/signaling.1.014","DOIUrl":"https://doi.org/10.46439/signaling.1.014","url":null,"abstract":"The prognosis of brain metastases in non-small cell lung cancer (NSCLC) is poor, and patients with EGFR mutations are more likely to have brain metastases. The epidermal growth factor receptor (EGFR) gene status has changed the direction of treatment for NSCLC patients with brain metastases. The development of EGFR tyrosine kinase inhibitors (EGFR-TKI) has prolonged the survival time of NSCLC patients with brain metastases. The treatment of patients with NSCLC brain metastases should be individualized according to the clinical symptoms, tumor stage, and different gene mutation status. As cancer is heterogeneous at the molecular level, related biomarker studies looking for individualized characteristics are recommended.","PeriodicalId":72543,"journal":{"name":"Cell signaling","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135738759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-03DOI: 10.46439/signaling.1.012
Chenghua Luo, Dengyu Ji, Wen Wang
{"title":"A vicious cycle happened in the progress of hyperhomocysteinemia, the same may exist in the development of cancer","authors":"Chenghua Luo, Dengyu Ji, Wen Wang","doi":"10.46439/signaling.1.012","DOIUrl":"https://doi.org/10.46439/signaling.1.012","url":null,"abstract":"","PeriodicalId":72543,"journal":{"name":"Cell signaling","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135695983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-26DOI: 10.46439/signaling.1.007
M. Chiariello, L. Gherardini
Glioblastoma Multiforme (GBM) is one of the most lethal human cancer types, with a 5-year survival rate of approximately 5%. A key reason for this is usually considered its poor accessibility to systemically administered drugs that only limitedly overcome the Blood Brain Barrier, ultimately causing the likely dismal appearance of recurrences. Here, we comment on our successful use, in GBM preclinical models, of novel thermogel based drug-delivery platforms for loco-regional treatment of tumor recurrences after primary surgery. The innovation as well as the pitfalls of our processes are outlined and discussed with an eye towards potential advancements in the realm of personalized medicine applications.
{"title":"Aiming for the brain: a new thermogel-based drug delivery platform","authors":"M. Chiariello, L. Gherardini","doi":"10.46439/signaling.1.007","DOIUrl":"https://doi.org/10.46439/signaling.1.007","url":null,"abstract":"Glioblastoma Multiforme (GBM) is one of the most lethal human cancer types, with a 5-year survival rate of approximately 5%. A key reason for this is usually considered its poor accessibility to systemically administered drugs that only limitedly overcome the Blood Brain Barrier, ultimately causing the likely dismal appearance of recurrences. Here, we comment on our successful use, in GBM preclinical models, of novel thermogel based drug-delivery platforms for loco-regional treatment of tumor recurrences after primary surgery. The innovation as well as the pitfalls of our processes are outlined and discussed with an eye towards potential advancements in the realm of personalized medicine applications.","PeriodicalId":72543,"journal":{"name":"Cell signaling","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85313161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：